SCHEMBL9605864

SCHEMBL9605864

CN(CCCN(CCCCNC(=O)OC(C)(C)C)C(=O)OC(C)(C)C)C(=O)c1ccc(Cl)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STK17B O94768 1/20 0.43
STK17A Q9UEE5 1/20 0.43
CA14 Q9ULX7 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CKS1B P61024 1/20 0.40
SKP1 P63208 1/20 0.40
SKP2 Q13309 1/20 0.40
CCNC P24863 1/20 0.40
CDK8 P49336 1/20 0.40
CA12 O43570 4/20 0.37
CA1 P00915 4/20 0.37
CA2 P00918 4/20 0.37
CA9 Q16790 4/20 0.37
GAA P10253 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
CYP3A4 P08684 1/20 0.37
DRD2 P14416 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PDK1 Q15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9605528 0.88 CA14 (0.40) STK17BSTK17ACA14MEN1KMT2A
SCHEMBL9605543 0.87 CA14 (0.46) STK17BSTK17ACA14MEN1KMT2A
SCHEMBL15064801 0.86 CA14 (0.47) STK17BSTK17ACA14MEN1KMT2A
SCHEMBL19414938 0.80 CA14 (0.41) STK17BSTK17ACA14MEN1KMT2A
SCHEMBL9605904 0.78 CA14 (0.46) STK17BSTK17ACA14MEN1KMT2A
SCHEMBL9605525 0.78 MEN1 (0.55) STK17BSTK17AMEN1KMT2ACA12
SCHEMBL14457277 0.76 CA14 (0.60) STK17BSTK17ACA14MEN1KMT2A
SCHEMBL15065050 0.75 CA14 (0.41) CA14MEN1KMT2AGAATDP1
SCHEMBL15065019 0.75 CA14 (0.44) STK17BSTK17ACA14MEN1KMT2A
SCHEMBL13055410 0.75 CA14 (0.68) STK17BSTK17ACA14MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2643301-B1 TECHNETIUM-99M COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS PF MEDICAMENT (FR) 2017-10-04 EP disclosed
US-20130171067-A1 TECHNETIUM-99m COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS PIERRE FABRE MEDICAMENT (FR) 2013-07-04 US disclosed
US-20130171067-A1 TECHNETIUM-99m COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS PIERRE FABRE MEDICAMENT (FR) 2013-07-04 US disclosed
WO-2012069608-A1 TECHNETIUM-99M COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS PIERRE FABRE MEDICAMENT (FR) 2012-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130171067-A1 TECHNETIUM-99m COMPLEX AS A TOOL FOR THE IN VIVO DIAGNOSIS OF CANCEROUS TUMOURS SLC40A1, CDC73, BRCA1 STK17B 3095/4885STK17A 3129/4885CA14 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.